Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma: an exploratory study related to the EORTC 90101 “CREATE” trial

Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma characterized by an unbalanced translocation, resulting in ASPSCR1-TFE3 fusion that transcriptionally upregulates MET expression. The European Organization for Research and Treatment of Cancer (EORTC) 90101 “CREATE” phase II...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lee, Che-Jui (VerfasserIn) , Modave, Elodie (VerfasserIn) , Boeckx, Bram (VerfasserIn) , Kasper, Bernd (VerfasserIn) , Aamdal, Steinar (VerfasserIn) , Leahy, Michael G. (VerfasserIn) , Rutkowski, Piotr (VerfasserIn) , Bauer, Sebastian (VerfasserIn) , Debiec-Rychter, Maria (VerfasserIn) , Sciot, Raf (VerfasserIn) , Lambrechts, Diether (VerfasserIn) , Wozniak, Agnieszka (VerfasserIn) , Schöffski, Patrick (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 19 May 2022
In: International journal of molecular sciences
Year: 2022, Jahrgang: 23, Heft: 10, Pages: 1-19
ISSN:1422-0067
DOI:10.3390/ijms23105689
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms23105689
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/23/10/5689
Volltext
Verfasserangaben:Che-Jui Lee, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael G. Leahy, Piotr Rutkowski, Sebastian Bauer, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak and Patrick Schöffski

MARC

LEADER 00000caa a2200000 c 4500
001 1881592553
003 DE-627
005 20240307075331.0
007 cr uuu---uuuuu
008 240226s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/ijms23105689  |2 doi 
035 |a (DE-627)1881592553 
035 |a (DE-599)KXP1881592553 
035 |a (OCoLC)1425215383 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Lee, Che-Jui  |e VerfasserIn  |0 (DE-588)1321714491  |0 (DE-627)1881593711  |4 aut 
245 1 0 |a Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma  |b an exploratory study related to the EORTC 90101 “CREATE” trial  |c Che-Jui Lee, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael G. Leahy, Piotr Rutkowski, Sebastian Bauer, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak and Patrick Schöffski 
246 1 |i Titel des übergeordneten Special issue  |a New strategies in therapeutic targets of soft tissue sarcoma 
264 1 |c 19 May 2022 
300 |a 19 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 26.02.2024 
520 |a Alveolar soft part sarcoma (ASPS) is a rare subtype of soft tissue sarcoma characterized by an unbalanced translocation, resulting in ASPSCR1-TFE3 fusion that transcriptionally upregulates MET expression. The European Organization for Research and Treatment of Cancer (EORTC) 90101 “CREATE” phase II trial evaluated the MET inhibitor crizotinib in ASPS patients, achieving only limited antitumor activity. We performed a comprehensive molecular analysis of ASPS tissue samples collected in this trial to identify potential biomarkers correlating with treatment outcome. A tissue microarray containing 47 ASPS cases was used for the characterization of the tumor microenvironment using multiplex immunofluorescence. DNA isolated from 34 available tumor samples was analyzed to detect recurrent gene copy number alterations (CNAs) and mutations by low-coverage whole-genome sequencing and whole-exome sequencing. Pathway enrichment analysis was used to identify diseased-associated pathways in ASPS sarcomagenesis. Kaplan-Meier estimates, Cox regression, and the Fisher’s exact test were used to correlate histopathological and molecular findings with clinical data related to crizotinib treatment, aiming to identify potential factors associated with patient outcome. Tumor microenvironment characterization showed the presence of PD-L1 and CTLA-4 in 10 and 2 tumors, respectively, and the absence of PD-1 in all specimens. Apart from CD68, other immunological markers were rarely expressed, suggesting a low level of tumor-infiltrating lymphocytes in ASPS. By CNA analysis, we detected a number of broad and focal alterations. The most common alteration was the loss of chromosomal region 1p36.32 in 44% of cases. The loss of chromosomal regions 1p36.32, 1p33, 1p22.2, and 8p was associated with shorter progression-free survival. Using whole-exome sequencing, 13 cancer-associated genes were found to be mutated in at least three cases. Pathway enrichment analysis identified genetic alterations in NOTCH signaling, chromatin organization, and SUMOylation pathways. NOTCH4 intracellular domain dysregulation was associated with poor outcome, while inactivation of the beta-catenin/TCF complex correlated with improved outcome in patients receiving crizotinib. ASPS is characterized by molecular heterogeneity. We identify genetic aberrations potentially predictive of treatment outcome during crizotinib therapy and provide additional insights into the biology of ASPS, paving the way to improve treatment approaches for this extremely rare malignancy. 
650 4 |a alveolar soft part sarcoma 
650 4 |a CREATE 
650 4 |a crizotinib 
650 4 |a gene alteration 
650 4 |a immunological characterization 
650 4 |a molecular profiling 
650 4 |a tumor microenvironment 
700 1 |a Modave, Elodie  |e VerfasserIn  |4 aut 
700 1 |a Boeckx, Bram  |e VerfasserIn  |4 aut 
700 1 |a Kasper, Bernd  |d 1974-  |e VerfasserIn  |0 (DE-588)12274764X  |0 (DE-627)082130736  |0 (DE-576)29340447X  |4 aut 
700 1 |a Aamdal, Steinar  |e VerfasserIn  |4 aut 
700 1 |a Leahy, Michael G.  |e VerfasserIn  |4 aut 
700 1 |a Rutkowski, Piotr  |e VerfasserIn  |4 aut 
700 1 |a Bauer, Sebastian  |e VerfasserIn  |4 aut 
700 1 |a Debiec-Rychter, Maria  |e VerfasserIn  |4 aut 
700 1 |a Sciot, Raf  |e VerfasserIn  |4 aut 
700 1 |a Lambrechts, Diether  |e VerfasserIn  |4 aut 
700 1 |a Wozniak, Agnieszka  |e VerfasserIn  |4 aut 
700 1 |a Schöffski, Patrick  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t International journal of molecular sciences  |d Basel : Molecular Diversity Preservation International, 2000  |g 23(2022), 10, Artikel-ID 5689, Seite 1-19  |h Online-Ressource  |w (DE-627)316340715  |w (DE-600)2019364-6  |w (DE-576)281194653  |x 1422-0067  |7 nnas  |a Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma an exploratory study related to the EORTC 90101 “CREATE” trial 
773 1 8 |g volume:23  |g year:2022  |g number:10  |g elocationid:5689  |g pages:1-19  |g extent:19  |a Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma an exploratory study related to the EORTC 90101 “CREATE” trial 
856 4 0 |u https://doi.org/10.3390/ijms23105689  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.mdpi.com/1422-0067/23/10/5689  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240226 
993 |a Article 
994 |a 2022 
998 |g 12274764X  |a Kasper, Bernd  |m 12274764X:Kasper, Bernd  |d 60000  |e 60000PK12274764X  |k 0/60000/  |p 4 
999 |a KXP-PPN1881592553  |e 449116519X 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title_sort":"Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma","subtitle":"an exploratory study related to the EORTC 90101 “CREATE” trial","title":"Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma"}],"name":{"displayForm":["Che-Jui Lee, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael G. Leahy, Piotr Rutkowski, Sebastian Bauer, Maria Debiec-Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Wozniak and Patrick Schöffski"]},"person":[{"display":"Lee, Che-Jui","given":"Che-Jui","role":"aut","family":"Lee"},{"display":"Modave, Elodie","role":"aut","given":"Elodie","family":"Modave"},{"display":"Boeckx, Bram","role":"aut","given":"Bram","family":"Boeckx"},{"display":"Kasper, Bernd","role":"aut","given":"Bernd","family":"Kasper"},{"display":"Aamdal, Steinar","role":"aut","given":"Steinar","family":"Aamdal"},{"family":"Leahy","display":"Leahy, Michael G.","role":"aut","given":"Michael G."},{"display":"Rutkowski, Piotr","given":"Piotr","role":"aut","family":"Rutkowski"},{"given":"Sebastian","role":"aut","display":"Bauer, Sebastian","family":"Bauer"},{"given":"Maria","role":"aut","display":"Debiec-Rychter, Maria","family":"Debiec-Rychter"},{"family":"Sciot","role":"aut","given":"Raf","display":"Sciot, Raf"},{"family":"Lambrechts","display":"Lambrechts, Diether","role":"aut","given":"Diether"},{"given":"Agnieszka","role":"aut","display":"Wozniak, Agnieszka","family":"Wozniak"},{"given":"Patrick","role":"aut","display":"Schöffski, Patrick","family":"Schöffski"}],"titleAlt":[{"title":"New strategies in therapeutic targets of soft tissue sarcoma"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1881592553","origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"19 May 2022"}],"note":["Gesehen am 26.02.2024"],"relHost":[{"pubHistory":["1.2000 -"],"language":["eng"],"part":{"volume":"23","year":"2022","text":"23(2022), 10, Artikel-ID 5689, Seite 1-19","extent":"19","pages":"1-19","issue":"10"},"title":[{"title":"International journal of molecular sciences","title_sort":"International journal of molecular sciences"}],"note":["Gesehen am 17.09.20"],"id":{"eki":["316340715"],"zdb":["2019364-6"],"issn":["1422-0067","1661-6596"]},"disp":"Correlation of immunological and molecular profiles with response to crizotinib in alveolar soft part sarcoma an exploratory study related to the EORTC 90101 “CREATE” trialInternational journal of molecular sciences","physDesc":[{"extent":"Online-Ressource"}],"recId":"316340715","origin":[{"publisherPlace":"Basel","publisher":"Molecular Diversity Preservation International","dateIssuedDisp":"2000-","dateIssuedKey":"2000"}],"titleAlt":[{"title":"IJMS"}],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"physDesc":[{"extent":"19 S."}],"id":{"eki":["1881592553"],"doi":["10.3390/ijms23105689"]}} 
SRT |a LEECHEJUIMCORRELATIO1920